Agios Pharmaceuticals Inc (AGIO) : Casdin Capital scooped up 51,500 additional shares in Agios Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 9, 2016. The investment management firm now holds a total of 148,000 shares of Agios Pharmaceuticals Inc which is valued at $6,929,360.Agios Pharmaceuticals Inc makes up approximately 8.49% of Casdin Capital’s portfolio.
Other Hedge Funds, Including , Financial Architects Inc added AGIO to its portfolio by purchasing 1,414 company shares during the most recent quarter which is valued at $66,203. Agios Pharmaceuticals Inc makes up approx 0.02% of Financial Architects Inc’s portfolio.Proshare Advisors reduced its stake in AGIO by selling 2,673 shares or 8.55% in the most recent quarter. The Hedge Fund company now holds 28,585 shares of AGIO which is valued at $1,245,734. Agios Pharmaceuticals Inc makes up approx 0.02% of Proshare Advisors’s portfolio.Profund Advisors reduced its stake in AGIO by selling 3,631 shares or 19.64% in the most recent quarter. The Hedge Fund company now holds 14,860 shares of AGIO which is valued at $647,599. Agios Pharmaceuticals Inc makes up approx 0.03% of Profund Advisors’s portfolio. S&co Inc sold out all of its stake in AGIO during the most recent quarter. The investment firm sold 3,400 shares of AGIO which is valued $166,430.Great West Life Assurance Co Can boosted its stake in AGIO in the latest quarter, The investment management firm added 1,202 additional shares and now holds a total of 3,002 shares of Agios Pharmaceuticals Inc which is valued at $146,948.
Agios Pharmaceuticals Inc opened for trading at $44.95 and hit $48.56 on the upside on Friday, eventually ending the session at $46.82, with a gain of 4.39% or 1.97 points. The heightened volatility saw the trading volume jump to 7,94,730 shares. Company has a market cap of $1,775 M.
On the company’s financial health, Agios Pharmaceuticals Inc reported $-0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.93. The company had revenue of $31.28 million for the quarter, compared to analysts expectations of $25.66 million. The company’s revenue was down -8.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.13 EPS.
Many Wall Street Analysts have commented on Agios Pharmaceuticals Inc. Sun Trust Rbsn Humphrey Initiated Agios Pharmaceuticals Inc on Mar 30, 2016 to “Buy”, Price Target of the shares are set at $57.
Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.